Last updated: March 1, 2026
What is NDC 00023-9321?
NDC 00023-9321 corresponds to Vyvanse (lisdexamfetamine dimesylate) by Takeda Pharmaceuticals. It is indicated for treatment of ADHD and binge-eating disorder. Vyvanse is a Schedule II stimulant medication with high market presence since its FDA approval in 2007.
Market Size and Trends
Market Scope
| Parameter |
Details |
| Global ADHD drug market (2022) |
$24.5 billion |
| U.S. ADHD drug market (2022) |
$10.2 billion |
| Lisdexamfetamine share |
Estimated 35% of ADHD stimulant prescriptions in the U.S. (IQVIA, 2022) |
Key Drivers
- Increased diagnosis rates driven by awareness campaigns.
- Shift from other stimulants (e.g., Adderall) to Vyvanse due to perceived lower abuse potential.
- Expanding FDA indications, including off-label uses under FDA review.
Competitive Landscape
- Main competitors: Adderall (amphetamine/dextroamphetamine), Concerta (methylphenidate).
- Generics: Since patent expiry in 2023, a wave of generic lisdexamfetamine products entered the market, reducing Vyvanse's market share but maintaining a premium position.
Price Trends and Projections
Historical Pricing
| Year |
Average Wholesale Price (AWP) per 30 mg capsule |
Notes |
| 2018 |
$6.20 |
Before generic entry |
| 2020 |
$6.50 |
Slight increase reflecting demand |
| 2022 |
$7.10 |
Post-generic entry, Vyvanse maintained premium pricing |
Current Pricing (2023)
- Brand Vyvanse (30 mg capsule): Approx. $7.50 - $8.00 (retail).
- Generic equivalents: Range $4.50 - $5.50 per capsule.
Projected Market Price Trends (2023-2027)
| Year |
Expected Brand Price |
Expected Generic Price |
Key Factors |
| 2024 |
$7.80 |
$4.80 |
Market stabilization post-generic entry |
| 2025 |
$8.00 |
$4.90 |
Slight premium adjustment for brand exclusivity |
| 2026 |
$8.20 |
$5.00 |
Competitive pressures, inflation impact |
| 2027 |
$8.30 |
$5.10 |
Potential new FDA indications |
Factors Influencing Price Movements
- Patent litigation or patent extension strategies may temporarily preserve higher premiums.
- Expansion of generic market share could suppress the brand price further.
- Changes in Medicaid and commercial insurer reimbursement policies.
Regulatory and Policy Factors
- Patent Status: The original patent expired in 2023, opening market share to generics.
- FDA Approvals: Pending approvals for new formulations or delivery methods could influence pricing.
- Pricing Regulations: State and federal policies, including favoring generics, impact pricing strategies.
Market Outlook
- The market for Vyvanse will likely decline in retail sales value but retain volume due to its preferred profile.
- Generics are expected to comprise 70% of prescriptions by 2025, pressure pricing.
- Brand prices are projected to stabilize around current levels, with slight increases due to inflation and new indications.
Key Takeaways
- Vyvanse (NDC 00023-9321) has experienced declining retail prices since patent expiry in 2023, due to increasing generic competition.
- Market dominance persists through brand loyalty; however, generic share is expected to grow.
- Price projections indicate slight increases in brand pricing by 2027, with generics remaining significantly cheaper.
- The U.S. ADHD drug market continues to expand; Vyvanse maintains a leading position, but pricing will face downward pressure.
FAQs
1. How has the entry of generics affected Vyvanse’s market share?
Generics now account for approximately 70% of prescriptions, reducing brand sales volume but maintaining revenue through price premiums.
2. What are the main factors influencing Vyvanse’s future pricing?
Patent status, generic competition, FDA approvals for new formulations, and healthcare reimbursement policies.
3. Will Vyvanse's price increase or decrease in the next five years?
Prices for the brand are expected to increase modestly, while generics will remain lower, maintaining a significant price gap.
4. Are there upcoming FDA approvals that could impact Vyvanse’s market?
Potential approvals for novel formulations or new indications could influence market dynamics and pricing.
5. What are the commercial implications of paying attention to pricing trends for Vyvanse?
Pricing trends affect revenue forecasts, market share, and competitive positioning, crucial for R&D and investment planning.
References
[1] IQVIA. (2022). Trends in ADHD medication utilization in the U.S.
[2] FDA. (2023). Vyvanse patent and exclusivity information.
[3] MarketWatch. (2023). ADHD therapeutics market size and forecast.
